IPP Bureau

Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology
Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology

By IPP Bureau - January 10, 2025

Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement

Merieux completes acquisition of Bureau Veritas' food testing activities in Canada and US
Merieux completes acquisition of Bureau Veritas' food testing activities in Canada and US

By IPP Bureau - January 10, 2025

The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities

ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe
ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe

By IPP Bureau - January 10, 2025

According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually

Windlas Biotech’s new injectable facility receives GMP certification
Windlas Biotech’s new injectable facility receives GMP certification

By IPP Bureau - January 10, 2025

The certification marks a new chapter in Windlas Biotech’s growth trajectory,

Carbogen Amcis successfully completed Swissmedic inspection of its Vionnaz facility
Carbogen Amcis successfully completed Swissmedic inspection of its Vionnaz facility

By IPP Bureau - January 10, 2025

The site’s GMP Certification has been successfully renewed

PM Modi lays foundation stone of Kris City and bulk Drug Park at Nakkapalli
PM Modi lays foundation stone of Kris City and bulk Drug Park at Nakkapalli

By IPP Bureau - January 09, 2025

The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs

Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification
Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification

By IPP Bureau - January 09, 2025

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024

Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107
Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107

By IPP Bureau - January 09, 2025

The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs

Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav
Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav

By IPP Bureau - January 09, 2025

Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors

JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health

By IPP Bureau - January 09, 2025

He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)

Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery

By IPP Bureau - January 09, 2025

Increases speed to market for drug developers working on nucleic acid therapeutics

GEON Performance Solutions acquires Foster Corporation
GEON Performance Solutions acquires Foster Corporation

By IPP Bureau - January 09, 2025

Acquisition expands high-value medical platform

Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical
Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical

By IPP Bureau - January 09, 2025

This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments
Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments

By IPP Bureau - January 09, 2025

The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life

ProBioGen expands protein and viral manufacturing to drive continued growth
ProBioGen expands protein and viral manufacturing to drive continued growth

By IPP Bureau - January 09, 2025

This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t

Latest Stories

Interviews

Packaging